Spots Global Cancer Trial Database for oral azacitidine
Every month we try and update this database with for oral azacitidine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia | NCT00528983 | Myelodysplastic... Chronic Myelomo... Acute Myelogeno... | Subcutaneous (S... Oral Azacitidin... Oral Azacitidin... | 18 Years - | Celgene | |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | NCT02250326 | Carcinoma, Non-... | nab-paclitaxel ... CC-486 Duravalumab | 18 Years - | Celgene | |
| A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) | NCT04887857 | Leukemia, Myelo... | CC-486 Venetoclax | 18 Years - | Celgene | |
| Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes | NCT05782127 | Untreated Myelo... | Onureg + Veneto... | 18 Years - | Groupe Francophone des Myelodysplasies | |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | NCT04803201 | Angioimmunoblas... Enteropathy-Ass... Follicular T-Ce... Mature T-Cell a... Monomorphic Epi... Nodal Periphera... Peripheral T-Ce... | Cyclophosphamid... Doxorubicin Vincristine Prednisone Etoposide Duvelisib Oral azacitidin... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | NCT05469737 | Myelodysplastic... | Oral Azacitidin... Placebo for Ora... | 18 Years - | Bristol-Myers Squibb | |
| The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS) | NCT01566695 | Myelodysplastic... | Oral Azacitidin... Placebo Best Supportiv ... | 18 Years - | Celgene | |
| The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS) | NCT01566695 | Myelodysplastic... | Oral Azacitidin... Placebo Best Supportiv ... | 18 Years - | Celgene | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | NCT04803201 | Angioimmunoblas... Enteropathy-Ass... Follicular T-Ce... Mature T-Cell a... Monomorphic Epi... Nodal Periphera... Peripheral T-Ce... | Cyclophosphamid... Doxorubicin Vincristine Prednisone Etoposide Duvelisib Oral azacitidin... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | NCT04803201 | Angioimmunoblas... Enteropathy-Ass... Follicular T-Ce... Mature T-Cell a... Monomorphic Epi... Nodal Periphera... Peripheral T-Ce... | Cyclophosphamid... Doxorubicin Vincristine Prednisone Etoposide Duvelisib Oral azacitidin... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT03450343 | Large B-Cell Di... | Oral azacitidin... R-ICE | 18 Years - | Medical University of South Carolina | |
| Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL | NCT03593018 | Relapsed Angioi... Refractory Angi... | Oral azacitidin... Romidepsin Bendamustine Gemcitabine | 18 Years - | The Lymphoma Academic Research Organisation | |
| Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant | NCT02374099 | Breast Neoplasm... | CC-486 Fulvestrant | 18 Years - | Celgene | |
| Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes | NCT02281084 | Myelodysplastic... | Oral Azacitidin... Durvalumab | 18 Years - | Celgene | |
| Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia | NCT05141682 | T-Cell Large Gr... | Oral Azacitidin... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission | NCT01757535 | Leukemia, Myelo... | Oral Azacitidin... Placebo | 55 Years - | Celgene | |
| Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality | NCT06370000 | Acute Myeloid L... | Oral Azacitidin... | 18 Years - | Virginia Commonwealth University | |
| A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | NCT02343536 | Lymphoma, Large... Lymphoma, Folli... | Oral Azacitidin... Rituximab cyclophosphamid... Vincristine Prednisone | 18 Years - | Celgene | |
| Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | NCT01519011 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | oral azacitidin... oral azacitidin... | 18 Years - | Celgene | |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission | NCT05197426 | Acute Myeloid L... | Oral Azacitidin... Placebo | 55 Years - | Bristol-Myers Squibb | |
| Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine) | NCT01845805 | Pancreatic Canc... | oral azacitidin... Observation | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | NCT02343536 | Lymphoma, Large... Lymphoma, Folli... | Oral Azacitidin... Rituximab cyclophosphamid... Vincristine Prednisone | 18 Years - | Celgene | |
| CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | NCT05162976 | Recurrent Class... Refractory Clas... | Nivolumab Oral Azacitidin... | 18 Years - | City of Hope Medical Center | |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | NCT02223052 | Hematological N... Non-Hodgkin's L... Hodgkin's Lymph... Lymphoma Multiple Myelom... Acute Myeloid L... Leukemia Myelodysplastic... Neoplasms Melanoma Breast Cancer Metastatic Brea... Non-Small Cell ... Small Cell Lung... Renal Cell Carc... Glioblastoma Mu... Osteosarcoma Sarcoma Thyroid Cancer Genitourinary | CC-486 Vidaza | 18 Years - | Celgene | |
| Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission | NCT01757535 | Leukemia, Myelo... | Oral Azacitidin... Placebo | 55 Years - | Celgene | |
| Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant | NCT02374099 | Breast Neoplasm... | CC-486 Fulvestrant | 18 Years - | Celgene | |
| A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes | NCT01571648 | Myelodysplastic... | Oral azacitidin... | 20 Years - | Celgene | |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | NCT04578600 | Indolent B-Cell... Recurrent B-Cel... Recurrent Chron... Recurrent Mucos... Recurrent Folli... Recurrent Hairy... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Chro... Refractory Muco... Refractory Foll... Refractory Hair... Refractory Lymp... Refractory Mant... Refractory Marg... Recurrent Small... Refractory Smal... | Lenalidomide Obinutuzumab Oral Azacitidin... | 18 Years - | University of California, Davis | |
| Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT03450343 | Large B-Cell Di... | Oral azacitidin... R-ICE | 18 Years - | Medical University of South Carolina |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
